More than 30,000 people in the United States took part in modernas phase 3 study. Among them 95 were confirmed to have covid19 two weeks after the vaccine. 90 were observed in the placebo group, and five in the vaccinated group. 11 developed severe cases, all within the placebo group. Based on their interim analysis of the data the firm estimates the vaccine had an estimated 94. 5 efficacy and says there were no significant safety concerns. Moderna is part of the United States operation wp spee ich as to accelerate the e hd of e programays the and dernaaccine wld b eas t administer bauseheaccine cabe stored at standar to a month. Temraturesor up as oppos tthe pfizer vaccin which will require specialized storage to ensure temperates remain between minus 60 and minus 80 degrees celsius. If approved by regulators, moderna expects to have about 20 million doses ready to ship in the u. S. By the end of this year and is on track to manufacture up to 1 billion doses for global use in 2021. An